Sinopharm Group: Mixed Read-Throughs From Peer Disclosures And Management Guidance
Source: SeekingAlpha
2025-04-17 11:06:04 ET
Summary
- I maintain a Neutral rating for Sinopharm Group, considering sector-specific challenges and the company's favorable guidance.
- SHTDF's peers Shanghai Pharmaceuticals and China Resources Pharmaceutical have highlighted headwinds like lower drug prices and extended cash collection periods.
- But SHTDY's status as a pure-play distributor and its scale advantage over competitors could possibly drive market share gains.
- Sinopharm is fairly valued based on a PEG ratio of 1x.
I continue to have a Neutral opinion of Sinopharm Group Co. Ltd. ( SHTDY ) ( SHTDF ) (1099.HK) or "SGCL."...
Read the full article on Seeking Alpha
For further details see:
Sinopharm Group: Mixed Read-Throughs From Peer Disclosures And Management Guidance
Sinopharm Group Co. Ltd. ADR
NASDAQ: SHTDY
SHTDY Trading
-0.55% G/L:
$13.0801 Last:
11,149 Volume:
$13.01 Open:
